Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study suggests that a combination of topical minoxidil with oral finasteride and dutasteride may promote new hair growth in androgenetic alopecia, with minor safety concerns reported.

This research focused on formulating finasteride, dutasteride, and minoxidil with cyclodextrins to enhance their solubility and skin penetration for topical use, potentially reducing scalp irritation from current alcohol-based preparations.

This review discusses androgenetic alopecia management with 5α-reductase inhibitors, emphasizing that while dutasteride shows superior efficacy, finasteride is suggested as preferable due to predictable adverse effects and preservation of physiological roles.

This abstract lists a range of drugs and treatment agents like Abatacept, Amiodarone, and Remdesivir, but does not report any study results or findings.

This article reviews the progress in hair biology research, including advancements in understanding androgen action, hair follicle stem cells, and autoimmune mechanisms in alopecia, and reports no new clinical results.

In this case report, a female patient with frontal fibrosing alopecia and lichen scleroatrophicus vulvae experienced excellent results from hair microtransplants combined with finasteride and topical minoxidil, maintained over six years.

This review discusses common skin disorders in older women and their treatments, but it reports no new clinical results.

In this study, after long-term observation of human scalp hair follicles over 16 years, the researchers found that a topical 5% minoxidil solution could stimulate hair regrowth after a period of dormancy, though with reduced growth rates and hair diameter.

In this study, cetosomal-based minoxidil solutions, with and without finasteride, were observed to be effective and tolerable treatments for androgenetic alopecia in adults, providing a potential alternative to traditional alcoholic formulations.

This review discusses various treatments for hair loss, such as topical agents, oral minoxidil, and laser therapies, but reports no new clinical results; debates on issues like post-finasteride syndrome are also covered.

The authors concluded that pattern hair loss is a complex condition with limited treatment efficacy and two FDA-approved drugs, finasteride and minoxidil, to slow its progression.

This article summarizes expert opinions from Indian dermatologists on managing androgenetic alopecia and telogen effluvium, emphasizing varied treatments based on individual patterns and responses.

This review discusses current medical therapies available for treating hair loss and emphasizes the importance of understanding these options, but it presents no new results.

This review discusses male androgenetic alopecia treatments, noting that topical minoxidil and oral finasteride are FDA-approved and require continuous use to maintain hair retention effects, but reports no new clinical results.

This research highlights that while minoxidil and 5-alpha reductase inhibitors are commonly used for treating pattern hair loss, there is limited evidence supporting their relative effectiveness in women compared to men.

This research describes CG2001's promising safety profile and reduced systemic exposure as an alternative to finasteride, supporting its further development for androgenic alopecia treatment in future trials.

This study analyzed 57 medicinal and cosmetic preparations available in Poland for treating alopecia, finding that finasteride is the most common active ingredient, with many products being in tablet or shampoo form and categorized as prescription drugs and cosmetics.

This study found that combining PRP with topical minoxidil or finasteride significantly improved hair density and thickness, with patient satisfaction highest for multiple treatment combinations and longer durations.

Minoxidil is an effective and safe treatment for common hair loss when applied to the skin, but more research is needed for optimal use.

This review discusses the current therapeutic options for female pattern hair loss and emphasizes the need for managing patient expectations of permanent regrowth, reporting no new clinical results.

This study compiles current scientific knowledge on female pattern hair loss for aesthetic physicians, but it does not present new clinical findings.

This review concluded that oral finasteride for men and topical minoxidil for both genders have the most evidence supporting their effectiveness and safety for treating androgenetic alopecia.

This study found that finasteride-loaded microemulsions using poloxamer 124 significantly enhanced skin penetration of the drug compared to a standard solution, primarily through targeting hair follicles via the transfollicular pathway, with intercluster, intercellular, and transcellular pathways contributing less.

This study found that artocarpin delivered via alginate/chitosan microparticles effectively suppressed the growth of hamster flank organs compared to artocarpin in solution form, without significant systemic effects.

In this study of patients with androgenetic alopecia, botulinum toxin type A was found to significantly increase hair counts and improve hair density and coverage, with enhanced results observed when combined with oral finasteride, revealing a safe and effective treatment approach without adverse effects.

In this 10-patient exploratory study, the researchers found that topical application of 4-aminopyridine 5% combined with microneedling did not improve hair density or quality in men with androgenetic alopecia, suggesting limited efficacy in this context despite promising results in animal wound models.

In this research review, the authors note that while topical minoxidil and oral finasteride are FDA-approved treatments for male androgenetic alopecia, some patients experience inadequate responses or side effects, prompting exploration of alternative therapies like newer 5-α reductase inhibitors and androgen receptor antagonists.

Formononetin, found in red clover, may treat hair loss with fewer side effects.

This review discusses current treatment options for androgenetic alopecia, noting that most lack robust evidence for efficacy and safety, highlighting the need for more comprehensive studies.

This article discusses the development of an evidence-based guideline for treating androgenetic alopecia and reports no new research results.